This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
2/10/2026
Operator
Conference Operator
Greetings and welcome to Edwards Life Sciences' fourth quarter 2025 results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the conference over to your hosts,
Gerri-Ann Sarte
Senior Vice President, Investor Relations
Gerri-Ann Sarte. Thank you. You may begin. Thank you.
Gerri-Ann Sarte
Senior Vice President, Investor Relations
Good afternoon and thank you for joining us. This is Gerri-Ann Sarte. I am the incoming Senior Vice President of Investor Relations. With me on today's call is our CEO, Bernard Zavigian, and our CFO, Scott Ullum. Also joining us for the Q&A portion of the call will be Dan Lippis, our Global Leader of TAVR, and Devine Chopra, who has global responsibility for TMTT, Surgical, and IHFM. Just after the close of regular trading, Edwards Life Sciences released fourth quarter and full year 2025 financial results. During today's call, management will discuss the results included in the press release and accompanying financial results.
You're reading a preview of the EW Q4 2025 earnings call.
Free account.
Disclaimer